DOI:
10.1055/s-00000075
Seminars in Respiratory and Critical Care Medicine
LinksClose Window
References
FitzGerald JM, Bleecker ER, Nair P. , et al; CALIMA study investigators.
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet 2016;
388 (10056): 2128-2141
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.